AbbVie (ABBV) Tops Q3 EPS by 7c, Raises FY Guidance
AbbVie (NYSE: ABBV) reported Q3 EPS of $2.83, $0.07 better than the analyst estimate of $2.76. Revenue for the quarter came in at $12.9 billion versus the consensus estimate of $12.72 billion.
AbbVie sees FY2020 EPS of $10.47-$10.49, versus the consensus of $10.72.
- AbbVie is updating its GAAP diluted EPS guidance for the full-year 2020 from $4.12 to $4.22 to $3.89 to $3.91, which includes the results of Allergan from May 8, 2020 through December 31, 2020.
- AbbVie is updating its adjusted diluted EPS for the full-year 2020 from $10.35 to $10.45 to $10.47 to $10.49, which includes the results of Allergan from May 8, 2020 through December 31, 2020, representing annualized net accretion from the Allergan transaction of 12 percent. The combined company's 2020 adjusted diluted EPS guidance excludes $6.58 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.
For earnings history and earnings-related data on AbbVie (ABBV) click here.